Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27952304 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2GRM5F2KDM4ETSHR | |
| SCHEMBL28038080 | 0.89 | KMT2A (0.43) | SMN1; SMN2TSHRMAOBALDH1A1MAPT | |
| SCHEMBL1899781 | 0.89 | KMT2A (0.43) | SMN1; SMN2TSHRMAOBALDH1A1MAPT | |
| SCHEMBL15375576 | 0.88 | KDM4E (0.36) | KDM4EMAOBL3MBTL1TDP1 | |
| SCHEMBL28038134 | 0.87 | FFAR1 (0.41) | F2KDM4EMAOBALDH1A1MAPT | |
| SCHEMBL15375563 | 0.87 | FFAR1 (0.41) | F2KDM4EMAOBALDH1A1MAPT | |
| SCHEMBL15375518 | 0.85 | FFAR1 (0.37) | KDM4ETSHRALDH1A1MAPT | |
| SCHEMBL27854360 | 0.84 | TSHR (0.43) | SMN1; SMN2F2KDM4ETSHRMAOB | |
| SCHEMBL1201002 | 0.84 | TSHR (0.43) | SMN1; SMN2F2KDM4ETSHRMAOB | |
| SCHEMBL1200636 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2662358-A1 | Catecholamine derivatives and prodrugs thereof | H. Lundbeck A/S (DK) | 2013-11-13 | — | — | EP | claimed |
| EP-2682382-B1 | Method for Producing Phenylacetamide Compound | SUMITOMO CHEMICAL CO (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-2662352-B1 | Method for Producing Phenylacetamide Compound | SUMITOMO CHEMICAL CO (JP) | 2016-11-09 | — | — | EP | disclosed |
| EP-3009437-A1 | A CATECHOLAMINE DERIVATIVE USEFUL FOR THE TREATMENT OF PARKINSON'S DISEASE | H. Lundbeck A/S (DK) | 2016-04-20 | — | — | EP | disclosed |
| EP-2397459-B1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-16 | — | — | EP | disclosed |
| EP-2197883-B1 | Catecholamine derivative useful for the treatment of parkinson's disease | LUNDBECK & CO AS H (DK) | 2015-11-18 | — | — | EP | disclosed |
| CN-103641731-B | The manufacture method of phenylacetyl amine compound | SUMITOMO CHEMICAL CO., LTD. (JP) | 2015-10-28 | — | — | CN | disclosed |
| CN-103588657-A | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL CO | 2014-02-19 | — | — | CN | disclosed |
| EP-2682382-A2 | Method for Producing Phenylacetamide Compound | Sumitomo Chemical Company, Limited (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-8624062-B2 | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2662358-A1 | Catecholamine derivatives and prodrugs thereof | H. Lundbeck A/S (DK) | 2013-11-13 | — | — | EP | disclosed |
| EP-2662352-A2 | Method for Producing Phenylacetamide Compound | Sumitomo Chemical Company, Limited (JP) | 2013-11-13 | — | — | EP | disclosed |
| EP-2397459-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | MRPL21, AADAC, ARSA | SMN1; SMN2 4638/4885GRM5 4110/4885F2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.